MedTrace Logo

Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population

NCT07388056 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 169

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:

• Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.

Conditions

  • Cancer-associated Thrombosis

Interventions

DRUG

Anticoagulant

warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC

Sponsors & Collaborators

  • Thammasat University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07388056 on ClinicalTrials.gov